Protocol Ledger

NCT06816914 · Phase II · RECRUITING

Perioperative NALIRIFOX (liposomal Irinotecan in Combination with Fluorouracil, Leucovorin, and Oxaliplatin) in Resectable Pancreatic Adenocarcinoma: Randomized Phase II Trial

Interventional Phase II clinical trial protocol NCT06816914 sponsored by Taichung Veterans General Hospital in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-03-05 Enrollment: 84 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06816914
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)84 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06816914
Protocol FieldVerified Registry Value
NCT IdentifierNCT06816914
Consolidated Lead SponsorTaichung Veterans General Hospital
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment84 participants (ESTIMATED)
Registered Start Date2025-03-05
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06816914
Hospital Research SiteLocationSite Profile
Kaohsiung Chang Gung Memorial HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->
Kaohsiung Medical University Chung-Ho Memorial HospitalKaohsiung City, TaiwanOpen Hospital Dossier ->
China Medical University HospitalTaichung, TaiwanOpen Hospital Dossier ->
Taichung Veterans General HospitalTaichung, TaiwanOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI